OIS@ASRS 2017 Videos

Vicken Karageozian, MD, president and chief medical officer of Allegro Ophthalmics, reports on Phase II data of lead candidate Luminate as sequential and combination therapy…

Opthea CEO & Managing Director Megan Baldwin, PhD, updates the status of Phase I and II dose-escalation studies of the company’s lead agent OPT-302 in…

CEO Jeff Cleland, PhD, reports the company is moving ahead with trial design for a single ascending-dose study of its candidate GB-102 for intravitreal injection…

Charles Semba, MD, played integral roles in the development of Lucentis, Xiidra, and more recently Forsight IV’s drug delivery technology. Now the chief medical officer…

Stephen Yoo, MD, chief medical officer of REGENXBIO, which utilizes adeno-associated virus to target disease, laid out the company’s plans to run its RGX-314 gene…

Oscar Cuzzani, MD, PhD, VP of clinical development, detailed the company’s two ophthalmology programs including cell replacement that could be used to treat dry AMD.…

Mohamed Genead, MD, chief medical officer of GenSight Biologics, updated OIS on the early-stage clinical progress of the company’s lead gene therapy product to treat…

Andre Witkin, MD, assistant professor, Tufts University School of Medicine, explains how OCT angiography could allow researchers to better visualize neovascular membranes. The images could…

Amir H. Kashani, MD, PhD, assistant professor of clinical ophthalmology, USC Roski Eye Institute, Keck Medicine of USC, demonstrates how a layered construction of OCT…

M. Francesca Cordeiro, MD, PhD, professor, UCL and Imperial College London, Western Eye Hospital London, introduces a promising new technology that could enable much earlier…

John Edwards, CEO of Drusolv Therapeutics, lays out the company’s plan to use statins as a treatment for intermediate AMD. The firm is based off…

Remis Bistras, CEO of ProFarma, lays out the company’s plan to improve the delivery and effective life of drugs that strengthen neuroprotectiveness in retina ganglion…